Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations

Journal of Cystic Fibrosis

Volumn 15, Issue 5, 2016, Pages 568-578

  Dekkers, Johanna F ^a   Van Mourik, Peter ^a   Vonk, Annelotte M ^a   Kruisselbrink, Evelien ^a   Berkers, Gitte ^a   de Winter de Groot, Karin M ^a   Janssens, Hettie M ^b   Bronsveld, Inez ^c   van der Ent, Cornelis K ^a   de Jonge, Hugo R ^d   Beekman, Jeffrey M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Curcumin; Cystic fibrosis; Genistein; Intestinal current measurements (ICM); Intestinal organoids; VX 770

Indexed keywords

CURCUMIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; GENISTEIN; IVACAFTOR; LUMACAFTOR; AMINOPHENOL DERIVATIVE; CHLORIDE CHANNEL STIMULATING AGENT; ENZYME INHIBITOR; QUINOLONE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CELL SWELLING; CYSTIC FIBROSIS; CYTOPLASM; DOSE RESPONSE; DRUG POTENTIATION; GENE MUTATION; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MEASUREMENT; PROTEIN EXPRESSION; RECTAL ORGANOID; RECTUM BIOPSY; WESTERN BLOTTING; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; ORGANOID; PATHOLOGY; PROCEDURES; RECTUM; THEORETICAL MODEL;

AMINOPHENOLS; CHLORIDE CHANNEL AGONISTS; CURCUMIN; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GENISTEIN; HUMANS; MODELS, THEORETICAL; MOLECULAR TARGETED THERAPY; MUTATION; ORGANOIDS; QUINOLONES; RECTUM;

EID: 84964968279     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.04.007     Document Type: Article

References (57)

1. [1] Collins, F.S., Cystic fibrosis: molecular biology and therapeutic implications. Science 256 (1992), 774–779.
2. [2] Riordan, J.R., CFTR function and prospects for therapy. Annu Rev Biochem 77 (2008), 701–726.
3. [3] Welsh, M.J., Smith, A.E., Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73 (1993), 1251–1254.
4. [4] Rogan, M.P., Stoltz, D.A., Hornick, D.B., Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 139 (2011), 1480–1490.
5. [5] Bell, S.C., De Boeck, K., Amaral, M.D., New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther S0163-7258 (2014), 00122–00123.
6. [6] Liu, X., Dawson, D.C., Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability. Biochemistry 53 (2014), 5613–5618.
7. [7] Van Goor, F. et-al, Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 108 (2011), 18843–18848.
8. [8] Van Goor, F. et-al, Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106 (2009), 18825–18830.
9. [9] Ikpa, P.T., Bijvelds, M.J.C., de Jonge, H.R., Cystic fibrosis: toward personalized therapies. Int J Biochem Cell Biol 52 (2014), 192–200.
10. [10] Rowe, S.M., Verkman, A.S., Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med, 3, 2013.
11. [11] Ramsey, B.W. et-al, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
12. [12] De Boeck, K. et-al, Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13 (2014), 674–680.
13. [13] Accurso, F.J. et-al, Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363 (2010), 1991–2003.
14. [14] Davies, J.C. et-al, Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187 (2013), 1219–1225.
15. [15] Boyle, M.P. et-al, A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2 (2014), 527–538.
16. [16] Wainwright, C.E. et-al, Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 365 (2011), 1663–1672.
17. [17] Char, J.E. et-al, A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. PLoS One, 9, 2014, e88564.
18. [18] French, P.J. et-al, Genistein activates CFTR Cl hsp sp=“0.10”− channels via a tyrosine kinase- and protein phosphatase-independent mechanism. Am J Physiol 273 (1997), C747–C753.
19. [19] Sears, C.L. et-al, Genistein and tyrphostin 47 stimulate CFTR-mediated Cl hsp sp=“0.10”− secretion in T84 cell monolayers. Am J Physiol 269 (1995), G874–G882.
20. [20] Melin, P. et-al, The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem Pharmacol 67 (2004), 2187–2196.
21. [21] Wang, W., Bernard, K., Li, G., Kirk, K.L., Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 282 (2007), 4533–4544.
22. [22] Bernard, K., Wang, W., Narlawar, R., Schmidt, B., Kirk, K.L., Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms. J Biol Chem 284 (2009), 30754–30765.
23. [23] Berger, A.L. et-al, Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl hsp sp=“0.10”− channel activity. J Biol Chem 280 (2005), 5221–5226.
24. [24] Eckford, P.D.W., Li, C., Ramjeesingh, M., Bear, C.E., Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 287 (2012), 36639–36649.
25. [25] Jih, K.-Y., Hwang, T.-C., Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A 110 (2013), 4404–4409.
26. [26] Moran, O., Galietta, L.J.V., Zegarra-Moran, O., Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 62 (2005), 446–460.
27. [27] Sohma, Y., Yu, Y.-C., Hwang, T.-C., Curcumin and genistein: the combined effects on disease-associated CFTR mutants and their clinical implications. Curr Pharm Des 19 (2013), 3521–3528.
28. [28] Yu, Y.-C. et-al, Curcumin and genistein additively potentiate G551D-CFTR. J Cyst Fibros 10 (2011), 243–252.
29. [29] Dekkers, J.F. et-al, A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 19 (2013), 939–945.
30. [30] Dekkers, J.F., van der Ent, C.K., Beekman, J.M., Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis, 1, 2013, e27112.
31. [31] Schwank, G. et-al, Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13 (2013), 653–658.
32. [32] Roth, D.M. et-al, Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol, 12, 2014, e1001998.
33. [33] Okiyoneda, T. et-al, Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 9 (2013), 444–454.
34. [34] Eckford, P.D.W. et-al, VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol 21 (2014), 666–678.
35. [35] Sato, T. et-al, Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469 (2011), 415–418.
36. [36] Sato, T. et-al, Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141 (2011), 1762–1772.
37. [37] Jung, P. et-al, Isolation and in vitro expansion of human colonic stem cells. Nat Med 17 (2011), 1225–1227.
38. [38] Sato, T., Clevers, H., Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340 (2013), 1190–1194.
39. [39] Lin, S. et-al, Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Assay Drug Dev Technol 8 (2010), 669–684.
40. [40] Phuan, P.-W. et-al, Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol 86 (2014), 42–51.
41. [41] Boinot, C., Jollivet Souchet, M., Ferru-Clément, R., Becq, F., Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing. J Pharmacol Exp Ther 350 (2014), 624–634.
42. [42] Roth, E.K. et-al, The K hsp sp=“0.10”+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS One, 6, 2011, e24445.
43. [43] Clancy, J.P. et-al, Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function. PLoS One, 8, 2013, e73905.
44. [44] Beekman, J.M. et-al, CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014. J Cyst Fibros 13 (2014), 363–372.
45. [45] Wang, F., Zeltwanger, S., Yang, I.C., Nairn, A.C., Hwang, T.C., Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 111 (1998), 477–490.
46. [46] Lansdell, K.A., Cai, Z., Kidd, J.F., Sheppard, D.N., Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl hsp sp=“0.10”− channels expressed in murine cell line. J Physiol Lond 524 Pt 2 (2000), 317–330.
47. [47] Derand, R., Bulteau-Pignoux, L., Becq, F., The cystic fibrosis mutation G551D alters the non-Michaelis–Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory Genistein binding site. J Biol Chem 277 (2002), 35999–36004.
48. [48] Ren, X.-Q. et-al, Function of the ABC signature sequences in the human multidrug resistance protein 1. Mol Pharmacol 65 (2004), 1536–1542.
49. [49] Lin, W.-Y., Jih, K.-Y., Hwang, T.-C., A single amino acid substitution in CFTR converts ATP to an inhibitory ligand. J Gen Physiol 144 (2014), 311–320.
50. [50] Veit, G. et-al, Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med, 6, 2014, 246ra97.
51. [51] Cholon, D.M. et-al, Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med, 6, 2014, 246ra96.
52. [52] Clancy, J.P. et-al, Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67 (2012), 12–18.
53. [53] Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol Pharm 4 (2007), 807–818.
54. [54] Yang, Z., Kulkarni, K., Zhu, W., Hu, M., Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem 12 (2012), 1264–1280.
55. [55] Strimpakos, A.S., Sharma, R.A., Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10 (2008), 511–545.
56. [56] De Boeck, K. et-al, New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 10:Suppl. 2 (2011), S53–S66.
57. [57] de Jonge, H.R. et-al, Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating using chambers. J Cyst Fibros 3:Suppl. 2 (2004), 159–163.